{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01755195",
      "OrgStudyIdInfo": {
        "OrgStudyId": "130044"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "13-C-0044"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "National Institutes of Health Clinical Center (CC)",
        "OrgClass": "NIH"
      },
      "BriefTitle": "Cabozantinib for Adults With Advanced Soft Tissue Sarcoma",
      "OfficialTitle": "A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2021",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 15, 2013",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "September 30, 2020",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 16, 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "December 18, 2012",
      "StudyFirstSubmitQCDate": "December 18, 2012",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 24, 2012",
        "StudyFirstPostDateType": "Estimate"
      },
      "ResultsFirstSubmitDate": "August 23, 2021",
      "ResultsFirstSubmitQCDate": "August 23, 2021",
      "ResultsFirstPostDateStruct": {
        "ResultsFirstPostDate": "September 16, 2021",
        "ResultsFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "November 9, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 10, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Alice Chen, M.D.",
        "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
        "ResponsiblePartyInvestigatorAffiliation": "National Cancer Institute (NCI)"
      },
      "LeadSponsor": {
        "LeadSponsorName": "National Cancer Institute (NCI)",
        "LeadSponsorClass": "NIH"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Background:\n\n- Cabozantinib is a cancer treatment drug that blocks the growth of new blood vessels in tumors. It can also block a chemical on tumor cells that allows the cells to grow. A similar drug, pazopanib, is used to treat types of cancer known as sarcomas. Researchers want to see if cabozantinib can be an effective treatment for types of soft tissue sarcoma that have not responded to earlier treatments.\n\nObjectives:\n\n- To test the effectiveness of cabozantinib for soft tissue sarcomas that have not responded to standard treatments.\n\nEligibility:\n\n- Individuals at least 18 years of age who have soft tissue sarcomas that have not responded to standard treatments.\n\nDesign:\n\nParticipants will be screened with a physical exam and medical history. Blood samples will be collected. Imaging studies and other tests will be used to study the tumor before the start of treatment.\nParticipants will take cabozantinib tablets daily for 28-day cycles of treatment. The tablets should be taken whole on an empty stomach.\nTreatment will be monitored with frequent blood tests and imaging studies.\nParticipants will continue to take cabozantinib for as long as the tumor does not become worse and the side effects are not too severe.",
      "DetailedDescription": "Background:\n\nSoft tissue sarcomas (STS) are a relatively rare heterogeneous group of tumors that constitute about 1% of adult cancers.\nThe mainstay of treatment for advanced disease has been palliative chemotherapy with a median overall survival of approximately 12 months. This has not changed considerably in the past years and there is an unmet need for newer targeted therapies.\nVascular endothelial growth factor (VEGF) levels are elevated in patients with STS and various sarcoma cell lines express high levels of activated c-Met receptor.\nWe hypothesize that dual targeting of the VEGF and mesenchymal-epithelial transition factor (c-MET) pathways with cabozantinib would result in clinical benefit in patients with soft tissue sarcoma.\n\nObjectives:\n\nPrimary:\n\nAssess the response rate (Complete Response (CR)+Partial Response (PR) of cabozantinib in patients with soft tissue sarcomas.\nAssess the 6 month progression free survival (PFS) of cabozantinib in soft tissue sarcomas.\n\nSecondary:\n\n-Determine and compare circulating levels of hepatocyte growth factor (HGF), soluble MET (sMET), VEGF-A, and soluble vascular endothelial growth factor receptor 2 (VEGFR2) (sVEGFR2) prior to and following administration of cabozantinib.\n\nEligibility:\n\nPatients must have had disease progression following one line of standard therapy\nAge greater than or equal to 18 years.\nAdequate organ function.\n\nDesign:\n\nAll patients will receive cabozantinib at 60 mg by mouth (PO) daily in 4 week cycles.\nTumor response evaluations by imaging will be done every 2 cycles (less frequently for patients on study more than one year).\nThe study will be conducted as a dual-endpoint two-stage Phase II trial to target objective tumor response rate (CR+PR) of 30% against an unacceptably low rate of 10%, and 6-month PFS rate of 65% against an unacceptably low rate of 45% (corresponding to median PFS of 9.6 vs. 5.2 months).\nThe trial will accrue up to 55 patients."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Refractory Soft Tissue Sarcomas"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Dual Inhibitor of MET and VEGFR",
          "XL184",
          "Metastatic Refractory",
          "Soft Tissue Sarcoma",
          "Rare Heterogeneous Tumor"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "55",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Cabozantinib",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "60 mg tablets orally once a day in a 28-day cycle.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Cabozantinib"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Cabozantinib",
            "InterventionDescription": "Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Cabozantinib"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Cometriq"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas",
            "PrimaryOutcomeDescription": "Objective response was assessed by the Response Evaluation Criteria in Solid Tumors RECIST) v1.1. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.",
            "PrimaryOutcomeTimeFrame": "Date treatment consent signed to date off study, approximately 86 months and 3 days."
          },
          {
            "PrimaryOutcomeMeasure": "Percentage of Participants With 6 Month Progression Free Survival (PFS)",
            "PrimaryOutcomeDescription": "Progression in participants with soft tissue sarcomas treated with cabozantinib was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions.",
            "PrimaryOutcomeTimeFrame": "6 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Mean Change From Baseline in Levels of Circulating Hepatocyte Growth Factor (HGF)",
            "SecondaryOutcomeDescription": "Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of HGF. HGF protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.",
            "SecondaryOutcomeTimeFrame": "Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1"
          },
          {
            "SecondaryOutcomeMeasure": "Mean Change From Baseline in Levels of Circulating Soluble Mesenchymal Epithelial Transition Factor (sMET)",
            "SecondaryOutcomeDescription": "Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble MET (sMET). sMET protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.",
            "SecondaryOutcomeTimeFrame": "Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1"
          },
          {
            "SecondaryOutcomeMeasure": "Mean Change From Baseline in Levels of Circulating Vascular Endothelial Growth Factor A (VEGF-A)",
            "SecondaryOutcomeDescription": "Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of VEGF-A. VEGF-A protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.",
            "SecondaryOutcomeTimeFrame": "Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1"
          },
          {
            "SecondaryOutcomeMeasure": "Mean Change From Baseline in Levels of Circulating Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR-2)",
            "SecondaryOutcomeDescription": "Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble VEGFR2 (sVEGFR-2). sVEGFR-2 protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome..",
            "SecondaryOutcomeTimeFrame": "Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)",
            "OtherOutcomeDescription": "Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.",
            "OtherOutcomeTimeFrame": "Date treatment consent signed to date off study, approximately 86 months and 3 days."
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "INCLUSION CRITERIA:\nPatients must have histologically or cytologically confirmed soft tissue sarcoma that is metastatic or unresectable and for which standard treatment that prolongs survival does not exist or is no longer effective.\nPatients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >20 mm with conventional techniques or as >10 mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam.\nPatients are allowed prior vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) therapy.\nAge greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of cabozantinib in patients <18 years of age, children are excluded from this study.\nEastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1 (Karnofsky >70%).\nLife expectancy > 3 months.\n\nPatients must have normal organ and marrow function as defined below:\n\nleukocytes greater than or equal to 3,000/mcL\nabsolute neutrophil count greater than or equal to 1,500/mcL\nplatelets greater than or equal to 100,000/mcL\ntotal bilirubin less than or equal to 1.5 times ULN\nAspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase(SGOT)/alanine aminotransferase (ALT) serum glutamic pyruvic transaminase(SGPT) less than or equal to 2.5 times institutional upper limit of normal creatinine within normal institutional limits\ncreatinine within normal institutional limits OR clearance greater than or equal to 60 mL/min/1.73 m(2) for patients with creatinine levels above institutional normal.\nhemoglobin greater than or equal to 9 g/dL\nserum albumin greater than or equal to 2.8g/dL\nlipase <2.0 times upper limit of normal (ULN) and no radiologic or clinical evidence of pancreatitis\nurine protein/creatinine ratio (UPCR) less than or equal to 1\nserum phosphorus calcium, magnesium and potassium greater than or equal to lower limit of normal (LLN)\nSubjects must have blood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility. Initiation or adjustment of BP medication is permitted prior to study entry provided that the average of three BP readings at the time of enrollment is less than or equal to 140/90 mmHg\nPatients must be able to swallow whole tablets. Tablets must not be crushed or chewed.\nThe effects of cabozantinib on the developing human fetus are unknown. For this reason and because receptor tyrosine kinases are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s).\n\nSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used.\n\n-Ability to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nPatients who have had anticancer therapy, including kinase inhibitors or any investigational agent within 4 weeks or 5 half-lives (whichever is shorter) (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered to baseline from adverse events (except alopecia and other non-clinically significant adverse events (AEs). Patients who have received prior cabozantinib or inhibitors of tyrosine-protein kinase mesenchymal epithelial transition factor (c-MET) or hepatocyte growth factor (HGF) are ineligible.\nThe subject has received radionuclide treatment within 6 weeks of the first dose of study treatment\nThe subject has received radiation therapy within 4 weeks (greater than or equal to 2 weeks for palliative radiation therapy)\nPatients with active brain metastases or carcinomatous meningitis or epidural disease are excluded from this clinical trial. Subjects with brain metastases previously treated with whole brain radiation or radiosurgery or subjects with epidural disease previously treated with radiation who are asymptomatic and have remained stable for 4 weeks and do not require steroid treatment for at least 2 weeks before starting study treatment are eligible. Neurosurgical resection of brain metastases or brain biopsy is permitted if completed at least 3 months before starting study treatment. Baseline brain imaging with contrast-enhanced CT or MRI scans for subjects with known brain metastases is required to confirm eligibility.\nEligibility of subjects receiving any medications or substances known to affect or with the potential to affect the activity of cabozantinib will be determined following review of their cases by the Principal Investigator. Patients who are taking enzyme-inducing anticonvulsant agents are not eligible.\nPatients with refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that could interfere with absorption.\nUncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\nPregnant women are excluded from this study because cabozantinib has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cabozantinib, breastfeeding should be discontinued if the mother is treated with cabozantinib.\nStrong inhibitors and inducers of cytochrome P450 3A4 (CYP3A4) can affect levels of cabozantinib and should be avoided whenever possible or switched to alternatives. Subjects requiring chronic concomitant treatment of strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's Wort) are not eligible for this study. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/; medical reference texts such as the Physicians Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over the-counter medicine or herbal product.\nHuman immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with cabozantinib. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.\nThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel). Low dose aspirin (less than or equal to 81 mg/day), low-dose warfarin (less than or equal to 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permitted. (Please note that there may be cases in which patients on study require anticoagulation for deep vein thrombosis (DVT)/pulmonary embolism (PE) management; this does not necessitate taking\n\nthe patient off study.)\n\nThe subject has experienced any of the following\n\nclinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\nhemoptysis of greater than or equal to 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment\nany other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment\nThe subject has radiographic evidence of cavitating pulmonary lesion(s).\nThe subject has tumor in contact with, invading, or encasing any major blood vessels\nThe subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib\n\nThe subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\nCardiovascular disorders including:\n\nCongestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening\nConcurrent uncontrolled hypertension defined as sustained BP > 140 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment\nAny history of congenital long QT syndrome\n\nAny of the following within 6 months before the first dose of study treatment:\n\nunstable angina pectoris\nclinically-significant cardiac arrhythmias\nstroke (including transient ischemic attack (TIA), or other ischemic event)\nmyocardial infarction\nthromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter (e.g. vena cava filter) are not eligible for this study)\n\nGastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:\n\nAny of the following within 28 days before the first dose of study treatment\n\nintra-abdominal tumor/metastases invading GI mucosa\nactive peptic ulcer disease,\ninflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis\nmalabsorption syndrome\n\nAny of the following within 6 months before the first dose of study treatment:\n\nabdominal fistula\ngastrointestinal perforation\nbowel obstruction or gastric outlet obstruction\nintra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more that 6 months before the first dose of study treatment.\nOther disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement within 3 months before the first dose of study therapy\n\nOther clinically significant disorders such as:\n\nserious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\nhistory of organ transplant, including allogeneic bone marrow transplant\nconcurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\nhistory of major surgery as follows:\n\ni. Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\n\nii. Minor surgery within 1 months of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications\n\nIn addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery\n\nThe subject is unable to swallow tablets\nThe subject has a corrected QT interval calculated by the Fridericia formula (QTcF) >500 ms within 28 days before enrollment. Note: if initial QTcF is found to be > 500 ms, two additional EKGs separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is less than or equal to 500 ms, the subject meets eligibility in this regard.\nThe subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.\nThe subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment.\nPatients should not have any clinical evidence of an active infection at the time of enrollment.\n\nINCLUSION OF WOMEN AND MINORITIES:\n\nBoth men and women of all races and ethnic groups are eligible for this trial.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "120 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Alice P Chen, M.D.",
            "OverallOfficialAffiliation": "National Cancer Institute (NCI)",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "National Institutes of Health Clinical Center, 9000 Rockville Pike",
            "LocationCity": "Bethesda",
            "LocationState": "Maryland",
            "LocationZip": "20892",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "11346874",
            "ReferenceType": "background",
            "ReferenceCitation": "Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranch√®re D, Sastre X, Vilain MO, Bonichon F, N'Guyen Bui B. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001 May 15;91(10):1914-26."
          },
          {
            "ReferencePMID": "8315424",
            "ReferenceType": "background",
            "ReferenceCitation": "Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, Parkinson DR. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993 Jul;11(7):1269-75."
          },
          {
            "ReferencePMID": "2504890",
            "ReferenceType": "background",
            "ReferenceCitation": "Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol. 1989 Sep;7(9):1208-16."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "NIH Clinical Center Detailed Web Page",
            "SeeAlsoLinkURL": "https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2013-C-0044.html"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "ResultsSection": {
    "ParticipantFlowModule": {
      "FlowGroupList": {
        "FlowGroup": [
          {
            "FlowGroupId": "FG000",
            "FlowGroupTitle": "Cabozantinib",
            "FlowGroupDescription": "60 mg tablets orally once a day in a 28-day cycle.\n\nCabozantinib: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2)."
          }
        ]
      },
      "FlowPeriodList": {
        "FlowPeriod": [
          {
            "FlowPeriodTitle": "Overall Study",
            "FlowMilestoneList": {
              "FlowMilestone": [
                {
                  "FlowMilestoneType": "STARTED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "55"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "42"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "NOT COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "13"
                      }
                    ]
                  }
                }
              ]
            },
            "FlowDropWithdrawList": {
              "FlowDropWithdraw": [
                {
                  "FlowDropWithdrawType": "Participant noncompliance",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "2"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Switched to alternative treatment",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "4"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Withdrawal by Subject",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Participant refused to start treatment",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Participant has been consented for another trial",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Refused further treatment",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "3"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Complicating disease/intercurrent illness",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "BaselineCharacteristicsModule": {
      "BaselineGroupList": {
        "BaselineGroup": [
          {
            "BaselineGroupId": "BG000",
            "BaselineGroupTitle": "Cabozantinib",
            "BaselineGroupDescription": "60 mg tablets orally once a day in a 28-day cycle.\n\nCabozantinib: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2)."
          }
        ]
      },
      "BaselineDenomList": {
        "BaselineDenom": [
          {
            "BaselineDenomUnits": "Participants",
            "BaselineDenomCountList": {
              "BaselineDenomCount": [
                {
                  "BaselineDenomCountGroupId": "BG000",
                  "BaselineDenomCountValue": "55"
                }
              ]
            }
          }
        ]
      },
      "BaselineMeasureList": {
        "BaselineMeasure": [
          {
            "BaselineMeasureTitle": "Age, Categorical",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "<=18 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Between 18 and 65 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "50"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": ">=65 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "5"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Age, Continuous",
            "BaselineMeasureParamType": "Mean",
            "BaselineMeasureDispersionType": "Standard Deviation",
            "BaselineMeasureUnitOfMeasure": "years",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "49.69",
                              "BaselineMeasurementSpread": "12.21"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Sex: Female, Male",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "Female",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "31"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Male",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "24"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "Hispanic or Latino",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "11"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Not Hispanic or Latino",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "43"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Unknown or Not Reported",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Race (NIH/OMB)",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "American Indian or Alaska Native",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "1"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Asian",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "10"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Black or African American",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "9"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "White",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "33"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "More than one race",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Unknown or Not Reported",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Region of Enrollment",
            "BaselineMeasureParamType": "Number",
            "BaselineMeasureUnitOfMeasure": "participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineClassTitle": "United States",
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "55"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "OutcomeMeasuresModule": {
      "OutcomeMeasureList": {
        "OutcomeMeasure": [
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas",
            "OutcomeMeasureDescription": "Objective response was assessed by the Response Evaluation Criteria in Solid Tumors RECIST) v1.1. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.",
            "OutcomeMeasurePopulationDescription": "1/55 participants did not start therapy.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureDispersionType": "95% Confidence Interval",
            "OutcomeMeasureUnitOfMeasure": "percentage of particpants",
            "OutcomeMeasureTimeFrame": "Date treatment consent signed to date off study, approximately 86 months and 3 days.",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Cabozantinib",
                  "OutcomeGroupDescription": "60 mg tablets orally once a day in a 28-day cycle.\n\nCabozantinib: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2)."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "54"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "11.1",
                              "OutcomeMeasurementLowerLimit": "4.2",
                              "OutcomeMeasurementUpperLimit": "22.6"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Percentage of Participants With 6 Month Progression Free Survival (PFS)",
            "OutcomeMeasureDescription": "Progression in participants with soft tissue sarcomas treated with cabozantinib was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions.",
            "OutcomeMeasurePopulationDescription": "1/55 participants did not start therapy.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureDispersionType": "95% Confidence Interval",
            "OutcomeMeasureUnitOfMeasure": "percentage of participants",
            "OutcomeMeasureTimeFrame": "6 months",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Cabozantinib",
                  "OutcomeGroupDescription": "60 mg tablets orally once a day in a 28-day cycle.\n\nCabozantinib: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2)."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "54"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "49.3",
                              "OutcomeMeasurementLowerLimit": "36.2",
                              "OutcomeMeasurementUpperLimit": "67.3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Mean Change From Baseline in Levels of Circulating Hepatocyte Growth Factor (HGF)",
            "OutcomeMeasureDescription": "Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of HGF. HGF protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.",
            "OutcomeMeasurePopulationDescription": "42/54 participants were analyzed for this outcome measure. One participant did not start therapy, and twelve participants did not participate in the optional biomarker testing.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Mean",
            "OutcomeMeasureDispersionType": "95% Confidence Interval",
            "OutcomeMeasureUnitOfMeasure": "pg/mL",
            "OutcomeMeasureTimeFrame": "Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Cabozantinib",
                  "OutcomeGroupDescription": "60 mg tablets orally once a day in a 28-day cycle.\n\nCabozantinib: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2)."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "42"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Baseline to Cycle 1 Day 1",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "-51.3",
                              "OutcomeMeasurementLowerLimit": "-235.5",
                              "OutcomeMeasurementUpperLimit": "151.0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Baseline to Cycle 2 Day 1",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "344.8",
                              "OutcomeMeasurementLowerLimit": "4.1",
                              "OutcomeMeasurementUpperLimit": "685.6"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Mean Change From Baseline in Levels of Circulating Soluble Mesenchymal Epithelial Transition Factor (sMET)",
            "OutcomeMeasureDescription": "Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble MET (sMET). sMET protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.",
            "OutcomeMeasurePopulationDescription": "42/54 participants were analyzed for this outcome measure. One participant did not start therapy, and twelve participants did not participate in the optional biomarker testing.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Mean",
            "OutcomeMeasureDispersionType": "95% Confidence Interval",
            "OutcomeMeasureUnitOfMeasure": "ng/mL",
            "OutcomeMeasureTimeFrame": "Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Cabozantinib",
                  "OutcomeGroupDescription": "60 mg tablets orally once a day in a 28-day cycle.\n\nCabozantinib: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2)."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "42"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Baseline to Cycle 1 Day 1",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "-6.1",
                              "OutcomeMeasurementLowerLimit": "-12.0",
                              "OutcomeMeasurementUpperLimit": "-0.3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Baseline to Cycle 2 Day1",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "16.4",
                              "OutcomeMeasurementLowerLimit": "3.4",
                              "OutcomeMeasurementUpperLimit": "29.4"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Mean Change From Baseline in Levels of Circulating Vascular Endothelial Growth Factor A (VEGF-A)",
            "OutcomeMeasureDescription": "Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of VEGF-A. VEGF-A protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.",
            "OutcomeMeasurePopulationDescription": "42/54 participants were analyzed for this outcome measure. One participant did not start therapy, and twelve participants did not participate in the optional biomarker testing.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Mean",
            "OutcomeMeasureDispersionType": "97.5% Confidence Interval",
            "OutcomeMeasureUnitOfMeasure": "pg/mL",
            "OutcomeMeasureTimeFrame": "Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Cabozantinib",
                  "OutcomeGroupDescription": "60 mg tablets orally once a day in a 28-day cycle.\n\nCabozantinib: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2)."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "42"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Baseline to Cycle 1 Day 1",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "5.6",
                              "OutcomeMeasurementLowerLimit": "-3.6",
                              "OutcomeMeasurementUpperLimit": "14.7"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Baseline to Cycle 2 Day 1",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "32.5",
                              "OutcomeMeasurementLowerLimit": "6.5",
                              "OutcomeMeasurementUpperLimit": "58.5"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Mean Change From Baseline in Levels of Circulating Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR-2)",
            "OutcomeMeasureDescription": "Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble VEGFR2 (sVEGFR-2). sVEGFR-2 protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome..",
            "OutcomeMeasurePopulationDescription": "42/54 participants were analyzed for this outcome measure. One participant did not start therapy, and twelve participants did not participate in the optional biomarker testing.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Mean",
            "OutcomeMeasureDispersionType": "95% Confidence Interval",
            "OutcomeMeasureUnitOfMeasure": "ng/mL",
            "OutcomeMeasureTimeFrame": "Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Cabozantinib",
                  "OutcomeGroupDescription": "60 mg tablets orally once a day in a 28-day cycle.\n\nCabozantinib: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2)."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "42"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Baseline to Cycle 1 Day 1",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "-1.0",
                              "OutcomeMeasurementLowerLimit": "-2.6",
                              "OutcomeMeasurementUpperLimit": "0.6"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Baseline to Cycle 2 Day 1",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "-10.9",
                              "OutcomeMeasurementLowerLimit": "-13.5",
                              "OutcomeMeasurementUpperLimit": "-8.4"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Other Pre-specified",
            "OutcomeMeasureTitle": "Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)",
            "OutcomeMeasureDescription": "Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.",
            "OutcomeMeasurePopulationDescription": "1/55 participants did not start therapy.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "Date treatment consent signed to date off study, approximately 86 months and 3 days.",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Cabozantinib",
                  "OutcomeGroupDescription": "60 mg tablets orally once a day in a 28-day cycle.\n\nCabozantinib: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2)."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "54"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "53"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "AdverseEventsModule": {
      "EventsFrequencyThreshold": "0",
      "EventsTimeFrame": "Date treatment consent signed to date off study, approximately 86 months and 3 days.",
      "EventsDescription": "1/55 participants did not start therapy.",
      "EventGroupList": {
        "EventGroup": [
          {
            "EventGroupId": "EG000",
            "EventGroupTitle": "Cabozantinib",
            "EventGroupDescription": "60 mg tablets orally once a day in a 28-day cycle.\n\nCabozantinib: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).",
            "EventGroupDeathsNumAffected": "3",
            "EventGroupDeathsNumAtRisk": "54",
            "EventGroupSeriousNumAffected": "14",
            "EventGroupSeriousNumAtRisk": "54",
            "EventGroupOtherNumAffected": "53",
            "EventGroupOtherNumAtRisk": "54"
          }
        ]
      },
      "SeriousEventList": {
        "SeriousEvent": [
          {
            "SeriousEventTerm": "Abdominal pain",
            "SeriousEventOrganSystem": "Gastrointestinal disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "2",
                  "SeriousEventStatsNumAffected": "2",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Anemia",
            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Cerebrospinal fluid leakage",
            "SeriousEventOrganSystem": "Nervous system disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Dehydration",
            "SeriousEventOrganSystem": "Metabolism and nutrition disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "3",
                  "SeriousEventStatsNumAffected": "2",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Diarrhea",
            "SeriousEventOrganSystem": "Gastrointestinal disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Dyspnea",
            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Fatigue",
            "SeriousEventOrganSystem": "General disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "General disorders and administration site conditions - Other, fever",
            "SeriousEventOrganSystem": "General disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Headache",
            "SeriousEventOrganSystem": "Nervous system disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Hematuria",
            "SeriousEventOrganSystem": "Renal and urinary disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Hypophosphatemia",
            "SeriousEventOrganSystem": "Metabolism and nutrition disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Muscle weakness trunk",
            "SeriousEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Nausea",
            "SeriousEventOrganSystem": "Gastrointestinal disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "3",
                  "SeriousEventStatsNumAffected": "3",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, neoplasm",
            "SeriousEventOrganSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Pleural effusion",
            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "2",
                  "SeriousEventStatsNumAffected": "2",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Pleuritic pain",
            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Pneumothorax",
            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Respiratory failure",
            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Serum amylase increased",
            "SeriousEventOrganSystem": "Investigations",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Small intestinal obstruction",
            "SeriousEventOrganSystem": "Gastrointestinal disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "2",
                  "SeriousEventStatsNumAffected": "2",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Stroke",
            "SeriousEventOrganSystem": "Nervous system disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Supraventricular tachycardia",
            "SeriousEventOrganSystem": "Cardiac disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Syncope",
            "SeriousEventOrganSystem": "Nervous system disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Thromboembolic event",
            "SeriousEventOrganSystem": "Vascular disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "4",
                  "SeriousEventStatsNumAffected": "3",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Tooth infection",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Transient ischemic attacks",
            "SeriousEventOrganSystem": "Nervous system disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Upper respiratory infection",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Urinary tract infection",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Vomiting",
            "SeriousEventOrganSystem": "Gastrointestinal disorders",
            "SeriousEventSourceVocabulary": "CTCAE (4.0)",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "3",
                  "SeriousEventStatsNumAffected": "3",
                  "SeriousEventStatsNumAtRisk": "54"
                }
              ]
            }
          }
        ]
      },
      "OtherEventList": {
        "OtherEvent": [
          {
            "OtherEventTerm": "Abdominal pain",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "25",
                  "OtherEventStatsNumAffected": "9",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Activated partial thromboplastin time prolonged",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "14",
                  "OtherEventStatsNumAffected": "6",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Alanine aminotransferase increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "61",
                  "OtherEventStatsNumAffected": "28",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Alkaline phosphatase increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "27",
                  "OtherEventStatsNumAffected": "21",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Allergic reaction",
            "OtherEventOrganSystem": "Immune system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Allergic rhinitis",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Alopecia",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "9",
                  "OtherEventStatsNumAffected": "6",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Anal hemorrhage",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Anemia",
            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "32",
                  "OtherEventStatsNumAffected": "13",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Anorexia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "30",
                  "OtherEventStatsNumAffected": "19",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Anxiety",
            "OtherEventOrganSystem": "Psychiatric disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Arthralgia",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Arthritis",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Aspartate aminotransferase increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "51",
                  "OtherEventStatsNumAffected": "24",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Back pain",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "7",
                  "OtherEventStatsNumAffected": "6",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Bladder perforation",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Bloating",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Blood and lymphatic system disorders - Other, Blood in stool due to hemorrhoids",
            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Blood bilirubin increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "7",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Blurred vision",
            "OtherEventOrganSystem": "Eye disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Bone pain",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Brachial plexopathy",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Bruising",
            "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "10",
                  "OtherEventStatsNumAffected": "9",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Bullous dermatitis",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "CPK increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Cataract",
            "OtherEventOrganSystem": "Eye disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Chest pain - cardiac",
            "OtherEventOrganSystem": "Cardiac disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Chest wall pain",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Chills",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Concentration impairment",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Confusion",
            "OtherEventOrganSystem": "Psychiatric disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Constipation",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "22",
                  "OtherEventStatsNumAffected": "16",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Cough",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "14",
                  "OtherEventStatsNumAffected": "9",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Creatinine increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dehydration",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "9",
                  "OtherEventStatsNumAffected": "6",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dental caries",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Depression",
            "OtherEventOrganSystem": "Psychiatric disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Diarrhea",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "72",
                  "OtherEventStatsNumAffected": "28",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dizziness",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "16",
                  "OtherEventStatsNumAffected": "11",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dry eye",
            "OtherEventOrganSystem": "Eye disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dry mouth",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "17",
                  "OtherEventStatsNumAffected": "12",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dry skin",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "10",
                  "OtherEventStatsNumAffected": "8",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dysgeusia",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "24",
                  "OtherEventStatsNumAffected": "17",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dyspepsia",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "10",
                  "OtherEventStatsNumAffected": "9",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dysphagia",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "6",
                  "OtherEventStatsNumAffected": "6",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dyspnea",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "15",
                  "OtherEventStatsNumAffected": "11",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Ear and labyrinth disorders - Other, Light headedness",
            "OtherEventOrganSystem": "Ear and labyrinth disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Ear pain",
            "OtherEventOrganSystem": "Ear and labyrinth disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Edema face",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Edema limbs",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "9",
                  "OtherEventStatsNumAffected": "7",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Electrocardiogram QT corrected interval prolonged",
            "OtherEventOrganSystem": "Cardiac disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Endocrine disorders - Other, Lactate dehydrogenase increased",
            "OtherEventOrganSystem": "Endocrine disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Enterocolitis",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Epistaxis",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "10",
                  "OtherEventStatsNumAffected": "7",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Esophageal pain",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Eye disorders - Other, Eye disorders; erythrodysesthesia syndrome",
            "OtherEventOrganSystem": "Eye disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Eye disorders - Other, Eye disorders; loss of peripheral vision",
            "OtherEventOrganSystem": "Eye disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Eye disorders - Other, High Spatial Frequencies",
            "OtherEventOrganSystem": "Eye disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Eye disorders - Other, Vision change (black spots)",
            "OtherEventOrganSystem": "Eye disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Fall",
            "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Fatigue",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "46",
                  "OtherEventStatsNumAffected": "23",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Fever",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "6",
                  "OtherEventStatsNumAffected": "6",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Flank pain",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Flashing lights",
            "OtherEventOrganSystem": "Eye disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Flatulence",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "9",
                  "OtherEventStatsNumAffected": "7",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Flu like symptoms",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Flushing",
            "OtherEventOrganSystem": "Vascular disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Gait disturbance",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Gastroesophageal reflux disease",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Gastrointestinal disorders - Other, GI:Increased Salivation",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Gastrointestinal disorders - Other, Gastrointestinal disorders - Other, specify: Rectal discharge",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Gastrointestinal disorders - Other, blood in stool",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Gastrointestinal disorders - Other, intermittent decrease/loss of appetite",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Gastrointestinal disorders - Other, loose stool",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "General disorders and administration site conditions - Other, Mouth Sores",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "General disorders and administration site conditions - Other, Numbness of Tongue",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Gingival pain",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Gum infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hair color changes",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Headache",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "42",
                  "OtherEventStatsNumAffected": "20",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hematuria",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "9",
                  "OtherEventStatsNumAffected": "7",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hemoglobinuria",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hiccups",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hoarseness",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "11",
                  "OtherEventStatsNumAffected": "9",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hot flashes",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypercalcemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hyperglycemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "8",
                  "OtherEventStatsNumAffected": "6",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hyperkalemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "9",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypermagnesemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypernatremia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hyperphosphatemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypertension",
            "OtherEventOrganSystem": "Vascular disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "436",
                  "OtherEventStatsNumAffected": "43",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hyperthyroidism",
            "OtherEventOrganSystem": "Endocrine disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "8",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypoalbuminemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "37",
                  "OtherEventStatsNumAffected": "17",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypocalcemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "13",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypoglycemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypokalemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "10",
                  "OtherEventStatsNumAffected": "7",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypomagnesemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "10",
                  "OtherEventStatsNumAffected": "6",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hyponatremia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "16",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypophosphatemia",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "27",
                  "OtherEventStatsNumAffected": "14",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypotension",
            "OtherEventOrganSystem": "Vascular disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "8",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypothyroidism",
            "OtherEventOrganSystem": "Endocrine disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "26",
                  "OtherEventStatsNumAffected": "18",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Immune system disorders - Other, Liver Function Enzymes",
            "OtherEventOrganSystem": "Immune system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Infections and infestations - Other, Facial infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Infections and infestations - Other, Infection - Tumor fungation",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Infections and infestations - Other, Malaria",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Infections and infestations - Other, Post-dental work",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Infections and infestations - Other, Urine",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Infections and infestations - Other, Viral Infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Injury, poisoning and procedural complications - Other, Urine PCR",
            "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Insomnia",
            "OtherEventOrganSystem": "Psychiatric disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Investigations - Other, Hyperphosphatemia",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Investigations - Other, Lactate dehydrogenase increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Investigations - Other, Protein total decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Investigations - Other, Total protein decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Irregular menstruation",
            "OtherEventOrganSystem": "Reproductive system and breast disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Left ventricular systolic dysfunction",
            "OtherEventOrganSystem": "Cardiac disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Lipase increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "22",
                  "OtherEventStatsNumAffected": "10",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Lymphocyte count decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "46",
                  "OtherEventStatsNumAffected": "13",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Malaise",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Memory impairment",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Metabolism and nutrition disorders - Other, Early Satiety",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Middle ear inflammation",
            "OtherEventOrganSystem": "Ear and labyrinth disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Mucosal infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Mucositis oral",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "33",
                  "OtherEventStatsNumAffected": "14",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Muscle weakness lower limb",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Muscle weakness upper limb",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Musculoskeletal and connective tissue disorder - Other, intermittent muscle spasms",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Myalgia",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "15",
                  "OtherEventStatsNumAffected": "10",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Nail discoloration",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Nail infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Nail ridging",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Nasal congestion",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "6",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Nausea",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "50",
                  "OtherEventStatsNumAffected": "22",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Neck pain",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "9",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Neoplasms benign, malignant and unspecified",
            "OtherEventOrganSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "(incl cysts and polyps) - Other, Bleeding from tumor site",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Neuralgia",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Neutrophil count decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "66",
                  "OtherEventStatsNumAffected": "13",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Non-cardiac chest pain",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Oral hemorrhage",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Oral pain",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "11",
                  "OtherEventStatsNumAffected": "9",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pain",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "16",
                  "OtherEventStatsNumAffected": "10",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pain in extremity",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "15",
                  "OtherEventStatsNumAffected": "12",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pain of skin",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Palmar-plantar erythrodysesthesia syndrome",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "53",
                  "OtherEventStatsNumAffected": "29",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Paresthesia",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Periodontal disease",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Peripheral sensory neuropathy",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pharyngitis",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Photophobia",
            "OtherEventOrganSystem": "Eye disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Photosensitivity",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Platelet count decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "22",
                  "OtherEventStatsNumAffected": "15",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pleural effusion",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pneumonitis",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Postnasal drip",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Presyncope",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Proteinuria",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "27",
                  "OtherEventStatsNumAffected": "13",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pruritus",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Radiculitis",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Rash acneiform",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "6",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Rash maculo-papular",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Rectal pain",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Renal and urinary disorders - Other, Dysuria",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Renal and urinary disorders - Other, specify",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Nephrotic syndrome: Albumin 2.9 low, 24 hr Urine protein 3.58 , Edema.",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Renal and urinary disorders - Other, Protein Creatinine Ratio Increased",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Renal and urinary disorders - Other, Urine protein-Creatinine ratio increased",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Renal and urinary disorders - Other, elevated protein/creatinine ratio",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Renal and urinary disorders - Other, hesitancy",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Renal and urinary disorders - Other, proteinuria",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Respiratory, thoracic and mediastinal disorders - Other, URI with cold",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Respiratory, thoracic and mediastinal disorders - Other, bronchitis",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Rhinorrhea",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Serum amylase increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "57",
                  "OtherEventStatsNumAffected": "7",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Sinus bradycardia",
            "OtherEventOrganSystem": "Cardiac disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Sinus tachycardia",
            "OtherEventOrganSystem": "Cardiac disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Sinusitis",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, B/L lower extremity lacerations;",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, Cellulitis with fistula (supra-pubic area-LLQ)",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, Cellulitis with fistula (supra-pubic area-LLQ);",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, Chest Redness",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, Erythema along port",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, Graft dehiscence",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, Hair hypopigmentation",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "7",
                  "OtherEventStatsNumAffected": "7",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, Hair thinning",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, Lump on upper L chest wall",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, Pruritus /Rash acneiform",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, Seborrheic dermatitis",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, specify",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Skin and subcutaneous tissue disorders - Other, Lacerations",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, specify",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Skin and subcutaneous tissue disorders - Other, specify: Hair color change",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, Skin and subcutaneous tissue disorders - Other: hair",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, Skin discoloration (over R shoulder)",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, Skin lumps (face, ear, hairline)",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, fingernail splitting",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, hair lightening",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, hand purple/blue discoloration",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, intermittent petechiae bilateral breast",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, pin-size hole over port (no drainage)",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, sore on elbow",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, sunburn from swimming; chest, back, BUE",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other,",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin and subcutaneous tissue disorders - Other, specify",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventNotes": "Skin and subcutaneous tissue disorders - Other, specify: Hair color change",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin hyperpigmentation",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin hypopigmentation",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "12",
                  "OtherEventStatsNumAffected": "10",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Skin ulceration",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Sore throat",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "13",
                  "OtherEventStatsNumAffected": "12",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Spasticity",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Stomach pain",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Syncope",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Thromboembolic event",
            "OtherEventOrganSystem": "Vascular disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Thyroid stimulating hormone increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Tinnitus",
            "OtherEventOrganSystem": "Ear and labyrinth disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Tooth development disorder",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Tooth infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Toothache",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Tumor pain",
            "OtherEventOrganSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "9",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Upper respiratory infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "10",
                  "OtherEventStatsNumAffected": "7",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Urinary frequency",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Urinary retention",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Urinary tract infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "6",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Urinary tract pain",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Urinary urgency",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Urine discoloration",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Vaginal hemorrhage",
            "OtherEventOrganSystem": "Reproductive system and breast disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Vaginal infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Vaginal pain",
            "OtherEventOrganSystem": "Reproductive system and breast disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Vertigo",
            "OtherEventOrganSystem": "Ear and labyrinth disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Voice alteration",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Vomiting",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "42",
                  "OtherEventStatsNumAffected": "17",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Weight loss",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "46",
                  "OtherEventStatsNumAffected": "16",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Wheezing",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "White blood cell decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "66",
                  "OtherEventStatsNumAffected": "19",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "weight loss",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "CTCAE (4.0)",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "54"
                }
              ]
            }
          }
        ]
      }
    },
    "MoreInfoModule": {
      "CertainAgreement": {
        "AgreementPISponsorEmployee": "No",
        "AgreementRestrictiveAgreement": "No"
      },
      "PointOfContact": {
        "PointOfContactTitle": "Dr. Alice Chen",
        "PointOfContactOrganization": "National Cancer Institute",
        "PointOfContactEMail": "chenali@mail.nih.gov",
        "PointOfContactPhone": "240-781-3274"
      }
    }
  },
  "DocumentSection": {
    "LargeDocumentModule": {
      "LargeDocList": {
        "LargeDoc": [
          {
            "LargeDocTypeAbbrev": "Prot_SAP",
            "LargeDocHasProtocol": "Yes",
            "LargeDocHasSAP": "Yes",
            "LargeDocHasICF": "No",
            "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
            "LargeDocDate": "March 18, 2021",
            "LargeDocUploadDate": "07/30/2021 11:04",
            "LargeDocFilename": "Prot_SAP_000.pdf"
          },
          {
            "LargeDocTypeAbbrev": "ICF",
            "LargeDocHasProtocol": "No",
            "LargeDocHasSAP": "No",
            "LargeDocHasICF": "Yes",
            "LargeDocLabel": "Informed Consent Form",
            "LargeDocDate": "April 6, 2021",
            "LargeDocUploadDate": "06/04/2021 13:50",
            "LargeDocFilename": "ICF_001.pdf"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000012509",
            "ConditionMeshTerm": "Sarcoma"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000018204",
            "ConditionAncestorTerm": "Neoplasms, Connective and Soft Tissue"
          },
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M14479",
            "ConditionBrowseLeafName": "Sarcoma",
            "ConditionBrowseLeafAsFound": "Soft Tissue Sarcoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M19502",
            "ConditionBrowseLeafName": "Neoplasms, Connective and Soft Tissue",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T5284",
            "ConditionBrowseLeafName": "Soft Tissue Sarcoma",
            "ConditionBrowseLeafAsFound": "Soft Tissue Sarcoma",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M11052",
            "InterventionBrowseLeafName": "Mitogens",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M17833",
            "InterventionBrowseLeafName": "Endothelial Growth Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "T22",
            "InterventionBrowseLeafName": "Tyrosine",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "AA",
            "InterventionBrowseBranchName": "Amino Acids"
          }
        ]
      }
    }
  }
}